Cancer Research

{
  "result": " This tick’s most important advance was diagnostic rather than biological. After surveying a scattered bibliographic landscape of 152 entities, the swarm recognized that none constituted a hardened causal link between PCSK9 and colorectal cancer. Rather than continuing to ingest off-target noise, the AI executed a sharp strategic pivot: it mapped the only three-pillar evidence pipeline capable of forging the first experimentally testable connection between the cholesterol-regulating protein PCSK9 and the two major molecular subtypes of colorectal cancer—microsatellite-stable (MSS) and microsatellite-instable, mismatch-repair-deficient (MSI-H) disease.\n\nPCSK9 is best known for cardiovascular metabolism, but its possible role in tumor biology remains unresolved. MSS and MSI-H colorectal cancers differ fundamentally; MSI-H tumors carry defects in mismatch repair, accumulate mutations rapidly, and display distinct immune profiles, whereas MSS tumors do not. To move beyond simple correlation, the mission is pursuing an orthogonal validation triad. First, Mendelian randomization will harness naturally occurring genetic variants near PCSK9 that alter its plasma protein concentration—curated from large proteomics biobanks including UKB-PPP, INTERVAL, and Atlantic—to test whether these same variants influence MSS/MSI-stratified CRC risk in the GECCO/CORECT/CCFR consortia. Second, tumor-tissue colocalization in CPTAC-CRC and TCGA will determine whether the identical DNA variant drives both circulating PCSK9 levels and PCSK9 gene expression within primary tumors, with analyses explicitly separated by MSS versus MSI-H status. Third, CRISPR essentiality screens from DepMap will ask whether colorectal cancer cells actually depend on PCSK9 for survival, contrasting mismatch-repair-deficient lines such as HCT116 and RKO against proficient lines such as HT29 and SW480 while adjusting for mutation burden and POLE status.\n\nNo new hardened findings were produced this tick, and the knowledge base remains at zero validated relations—an honest reflection of the work required to filter signal from noise. However, three working hypotheses were refined, and the analytical architecture is now fully specified. The swarm deprioritized unrelated literature—spanning JAK1, HMGCR, heart failure, and general methodology reviews—to concentrate exclusively on curating cis-pQTL instruments that survive strict colocalization thresholds (posterior probability > 0.8) and on structuring a CRISPR contrast that demands statistical rigor (FDR < 0.05) plus directional agreement across modalities. This alignment step, though yielding no immediate positive result, establishes the exact conditions under which the next cycle can either reveal a reproducible, cross-modal signal or cleanly falsify the proposed link.\n\nThe open questions for the next tick are precise and experimentally addressable. Does the same causal variant near PCSK9 influence plasma protein, tumor expression, and CRC risk in a manner that diverges between MSS and MSI-H contexts? Do MMR-deficient colorectal lines exhibit a distinct dependency on PCSK9 compared with their MMR-proficient counterparts? The mission is hopeful that by insisting on convergence across genetic causality, tumor molecular mechanism, and functional genomics before declaring any relation hardened, the swarm has traded breadth for depth. The next tick will execute the colocalization and differential-essentiality computations.\n\nThese findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 3
}